Houston Baptist University has created a program that is training the next generation of cybersecurity professionals. Courtesy of HBU

A few years ago, Houston Baptist University realized there was a huge need for more engineering programs within Houston higher education in one area particularly: Cybersecurity.

The school brought in Stan Napper from Louisiana Tech University to become the founding dean of the College of Engineering. The college now has three bachelor's degree programs in cyber engineering, electrical engineering, and computer science.

"Cyber engineering is designing secure systems at the interface of operational technology and information technology," says Napper. "Cyber engineering is in the middle of devices and data. It's in the middle of the hardware and software. And, academically, it's in the middle of electrical engineering and computer science."

The program is the only of its kind in Texas, Napper says. In fact, he says he doesn't know of any other similar programs other than the one he was a part of at Louisiana Tech. However, he does expect that to change. There's a growing need for cybersecurity specialists — especially in the health care and energy industries.

"One of those things that really got my attention a couple of years ago is in 2017, the FDA issued a recall on the over 450,000 pacemakers that had already been implanted," Napper says. "Modern pacemakers now can be controlled remotely through the skin to change the pacing frequency or some other parameters of that pacemaker without having to go back and do another surgery. They discovered a software glitch to a particular brand of pacemaker that could have been exploited."

Thankfully, that glitch wasn't exploited, but it put thousands of people's lives at risk by those technology designers not foreseeing this cybersecurity glitch. Anywhere devices — not just computers or phones — are used remotely or on a network, security is compromised.

Napper has only one year of the program under his belt, but he says he has already seen a lot of interest from the school's advisory board, which is made up of 75 CTO and tech leaders.

"They're lining up to get our students as interns even before we have the students ready," Napper says. "We've only finished our first freshman class."

Napper says the program is on track to have a capacity of 200 to 250 students. At a school like HBU, which has around 3,400 total students, that's a huge chunk of the school's population. Some think the program, considering the need and reception, could grow to 1,000 students.

The courses cover everything within operational and intellectual technology — device design, data science, automation, artificial intelligence — and the students are already getting their hands dirty.

"Our approach to education is learning in context. It is very hands on, but it's not hands off or hands on sake," Napper says. "There's no single class in our inventory of courses where one person stands at the front and talks the whole time. Our students carry their lab with them to class. We changed the definition of a lab. A lab is not the place you go to once a week in order to write a lab report."

This fall, the school will have its inaugural class in sophomore-level courses and a new batch of freshmen. Down the road, Napper says they'll look into creating a master's program.

Michael Tims / Houston Bapitst U

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.